{
    "id": 29491,
    "fullName": "BRAF T599K",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "BRAF T599K lies within the protein kinase domain of the Braf protein (UniProt.org). T599K is predicted to lead to a gain of Braf protein function as indicated by increased Erk phosphorylation in culture, and is associated with resistance to Raf inhibitors (PMID: 31158244).",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "T599K",
    "createDate": "02/28/2019",
    "updateDate": "12/17/2019",
    "referenceTranscriptCoordinates": {
        "id": 178792,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140753339G>T",
        "cDna": "c.1796C>A",
        "protein": "p.T599K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19548,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment did not inhibit Erk phosphorylation in breast cancer cells expressing BRAF T599K in culture (PMID: 31158244).",
            "molecularProfile": {
                "id": 31523,
                "profileName": "BRAF T599K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16277,
                    "pubMedId": 31158244,
                    "title": "Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31523,
            "profileName": "BRAF T599K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178792,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140753339G>T",
            "cDna": "c.1796C>A",
            "protein": "p.T599K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178791,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140753339G>T",
            "cDna": "c.1796C>A",
            "protein": "p.T599K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}